vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
vTv Therapeutics Inc. - Class A (VTVT)
Last vtv therapeutics inc. - class a earnings: 7/31 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vtvtherapeutics.com
Company Research
Source: GlobeNewswire
HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced the submission of the study protocol to the FDA for the Company’s first Phase 3 trial evaluating the safety and efficacy of its lead candidate, cadisegliatin, in adults diagnosed with T1D. This randomized, double-blind, placebo-controlled trial is expected to enroll approximately 150 patients at up to 20 sites in the United States, with the first patient expected to be enrolled in the second quarter of 2024. The Phase 3 study will assess two doses of orally administered cadisegliatin versus placebo in patients currently being treated with multiple daily insulin injections and continuous subcutaneous insulin infusion, who use a continuous glucose monitor (CGM). The primary efficacy endpoint of the stud
Show less
Read more
Impact Snapshot
Event Time:
VTVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTVT alerts
High impacting vTv Therapeutics Inc. - Class A news events
Weekly update
A roundup of the hottest topics
VTVT
News
- CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT [Yahoo! Finance]Yahoo! Finance
- CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMITPR Newswire
- vTv Therapeutics Inc. (NASDAQ: VTVT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateGlobeNewswire
VTVT
Earnings
- 5/11/23 - Beat
VTVT
Sec Filings
- 4/25/24 - Form DEF
- 4/10/24 - Form S-3
- 3/26/24 - Form 8-K
- VTVT's page on the SEC website